Effects of Suhuang Zhike capsule combined with compound ipratropium bromide on treatment outcome in acute exacerbation of chronic obstructive pulmonary disease patients
Objective To observe the effect of Suhuang cough capsule combined with compound ipratropium on lung function,blood gas analysis index,and Thelper cell 17(Th17)/regulatory T cell(Treg)balance in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods Seventy-six AECOPD patients from March 2020 to March 2022 were divided into two groups,with 38 patients in each group.Control group:give compound ipratropium bromide,observation group:give Suhuang cough capsule combined with compound ipratropium bromide,compared with the two groups,clinical efficacy,indicators including lung function,blood gas analysis index,Th17/Treg balance,and adverse effects.Results The clinical total response rate in the observation group was significantly higher compared with the control group(P<0.05).After 2 weeks of treatment,FEV1,FVC,FEV1/FVC were higher in the observation group than in the control group(P<0.05).After 2 weeks of treatment,PaO2 was higher in the observation group and PaCO2 was lower than the control group(P<0.05).After 2 weeks of treatment,the Treg was higher than the control group,and the Th17 and Th17/Treg ratios were lower than the control group(P<0.05).The incidence of adverse reactions between the two groups showed no significant difference(P>0.05).Conclusion The combination of two drugs in AECOPD patients can help the improvement of clinical indicators,promote the Th17/Treg balance,and improve the clinical symptoms and have a good safety profile.
Pulmorary disease,chronic obstructiveIpratropiumBlood gas analysisRespirator function testsSuhuang Zhike capsule
万方数据
维普
